Literature DB >> 7665862

Density analysis of hepatitis C virus particle population in the circulation of infected hosts: implications for virus neutralization or persistence.

T Kanto1, N Hayashi, T Takehara, H Hagiwara, E Mita, M Naito, A Kasahara, H Fusamoto, T Kamada.   

Abstract

Hepatitis C virus has a low buoyant density in sucrose, but high-density particles are often observed in hepatitis C virus infection. To investigate the characteristics of circulating hepatitis C virus particles and their association with liver disease progression, we examined sera from two histologically normal hepatitis C virus carriers, 20 chronic hepatitis patients and five acute hepatitis C patients. The supernatants obtained after immunoprecipitation with anti-immunoglobulins antibody were subjected to sucrose equilibrium centrifugation. HCV-RNA positive fractions separated after the treatments were further examined for immunoprecipitation with anti-core hepatitis C virus antibody. We separated hepatitis C virus particle populations according to the density difference on 35% sucrose with centrifugation. The proportions of high and low density particles in hepatitis C virus populations were determined by means of competitive reverse transcription and polymerase chain reaction. Circulating hepatitis C virus particles in chronically infected patients could be separated into two populations: those immunoglobulin-bound with high densities and -unbound with low densities. Patients with severe liver inflammation had high-density hepatitis C virus that did not precipitate with anti-immunoglobulins but with anti-core hepatitis C virus antibodies. Thus, hepatitis C virus particle populations consist of low-density virions and high-density immune complexes and/or nucleocapsids. Among the chronic hepatitis patients, the dominant population shifted from low-density to high-density particles with the progression of liver disease. In acute hepatitis patients, this density shift was observed with alanine aminotransferase normalizations. Therefore, the major hepatitis C virus populations change from virion to immune complex and/or nucleocapsid with the progression of liver disease or inflammation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665862     DOI: 10.1016/0168-8278(95)80107-3

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  25 in total

1.  Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species.

Authors:  Robert S Tacke; Hai-Chon Lee; Celeste Goh; Jeremy Courtney; Stephen J Polyak; Hugo R Rosen; Young S Hahn
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

2.  Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway.

Authors:  Robert S Tacke; Annie Tosello-Trampont; Virginia Nguyen; David W Mullins; Young S Hahn
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

Review 3.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

4.  Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes.

Authors:  Bertrand Saunier; Miriam Triyatni; Luca Ulianich; Padma Maruvada; Paul Yen; Leonard D Kohn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes.

Authors:  Anna R Ciccaglione; Emilia Stellacci; Cinzia Marcantonio; Valentina Muto; Michele Equestre; Giulia Marsili; Maria Rapicetta; Angela Battistini
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

6.  Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients.

Authors:  P Maillard; K Krawczynski; J Nitkiewicz; C Bronnert; M Sidorkiewicz; P Gounon; J Dubuisson; G Faure; R Crainic; A Budkowska
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia.

Authors:  D Sansonno; G Lauletta; L Nisi; P Gatti; F Pesola; N Pansini; F Dammacco
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

8.  Characterization of low- and very-low-density hepatitis C virus RNA-containing particles.

Authors:  P André; F Komurian-Pradel; S Deforges; M Perret; J L Berland; M Sodoyer; S Pol; C Bréchot; G Paranhos-Baccalà; V Lotteau
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture.

Authors:  Kyung-Soo Chang; Jieyun Jiang; Zhaohui Cai; Guangxiang Luo
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

10.  Interaction of immune complexes isolated from hepatitis C virus-infected individuals with human cell lines.

Authors:  Rafael Marino; Leopoldo Deibis; Juan B De Sanctis; Nicolas E Bianco; Felix Toro
Journal:  Med Microbiol Immunol       Date:  2005-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.